DUBLIN–(BUSINESS WIRE)–The “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing” report has been added to ResearchAndMarkets.com’s offering.
This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022.
Targeted protein degradation is a strongly and rapidly emerging new therapeutic modality based on the promise to overcome limitations of traditional small molecule drug modalities, such as limited access to difficult-to-drug targets and development of drug resistance.
TPD technology is being adopted by most major pharmaceutical companies as it is regarded as a key technology platform. Pure-play TPD technology companies make progress by advancing their drug candidates into clinical studies. Many biotech companies are diversifying their platforms by adding TPD technology.
Investors welcome companies with TPD technologies as evidenced by the continuous flow of money to foster the development of TPD technology and TPD drug candidates. Since April of 2020, five pure-play TPD technology companies went public and successfully raised a total of US$ 2.14 bln.
The average market capitalization of five NASDAQ listed TPD technology companies was US$ 1.5 bln as of March 4, 2022. Series A-E financing rounds of 23 pure-play TPD technology companies brought in a total of US$ 1,778 mln of venture capital and equity investment. Partnering revenues are another important source of funding. As the TPD pipeline is maturing with favourable clinical outcomes, a recent licensing deal for a clinical phase II estrogen receptor PROTAC justified up-front payment and equity investment of US$ 1 bln.
This report describes and analyzes the industry landscape of targeted protein degradation by proteasomal-, lysosomal- and autophagy-targeted technologies. The report is based on information retrieved from 69 technology companies, 23 pharmaceutical companies and three academic institutions with publicly known industry ties.
Description of pharmaceutical companies generally is limited to activities with respect to TPD for publicly known in-house activities, for R&D collaboration and licensing and for acquisitions (Merck, Bayer, Amgen and Bristol Myers Squib).
The heterogeneous profiles of the 69 technology companies demands assignation to “clusters” of companies with similar characteristics to allow a systematic comparison of 33 pure-play TPD technology companies focused on proteasomal pathway or non-proteasomal pathway technologies; 26 technologically diversified companies with TPD technologies; and the remainder of 10 companies.
Specific profiles are provided for 31 TPD technologies, separately for proteasomal molecular glue/monovalent degrader; proteasomal heterobifunctional degraders, lysosomal & autophagy pathway degraders and the remainder.
Specific profiles are provided for 48 TPD drug candidates, separately for the same four TPD modalities as for TPD technologies.
All information in the three chapters of Company Profiles, Technology Profiles and Drug Candidate Profiles are fully referenced with 117 scientific references, in most cases with hyperlinks with immediate online access to the source of information (abstracts, Poster, Presentations).
Non-scientific references, such as press releases, annual reports or company presentations, are disclosed within the text with an embedded hyperlink leading to the source of information. Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles.
The report provides essential information about and analysis of:
Pure-play TPD technology companies (molecular glues, heterobifunctional degraders, lysosomal and autophagic pathway degraders)
Diversified technology companies with a TPD platform
Major pharma companies with a stake in TPD (in-house, partnering, licensing, acquisition)
Proteasomal protein degrader technologies (heterobifunctional, molecular glue, monovalent degrader)
Rational approaches for monofunctional molecular glue discovery at industry scale
Lysosomal and autophagy pathway degrader technologies (LYTACs, AUTOTACs, ATTECs etc)
Clinical and preclinical experience with molecular glues and PROTACs
Profiles of TPD Drug Candidates
TPD Pipeline Analysis
Preferred Targets of TPDs
Preferred E3 ligases and their binders
Technologies for discovery of binders to proteins-of-interest and E3 ligases
Venture capital financing of TPD technology companies
Financing by IPO and follow-on public offerings
Revenues from TPD discovery and licensing deals
Key Topics Covered:
1 Executive Summary
2 Introduction, Overview & Methodology
3 Analysis of TPD Stakeholders
3.1 Targeted Protein Degradation (TPD) Technology Companies
3.1.1 Overview
3.1.2 Pure-Play TPD Companies Focused on Molecular Glue & Monovalent Proteasomal Degraders
3.1.3 Pure-Play TPD Companies Focused on Heterobifunctional Proteasomal Degraders
3.1.4 Pure-Play TPD Companies Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders
3.1.5 Pure-Play TPD Companies Focused on Lysosomal & Autophagic (Non-Proteasomal) Degradation Technologies
3.1.6 Diversified Technology Companies with One Focus on Heterobifunctional Proteasomal Degraders
3.1.7 Diversified Technology Companies with Various TPD Technology Profiles
3.1.8 Remainder of Technology Companies with Various TPD Technology Profiles
3.2 Pharmaceutical Companies with TPD Interests
3.2.1 Overview of Major Pharma Companies as Stakeholders in TPD
3.2.2 Profile of Major Pharma’s Interest in Targeted Protein Degradation (TPD) R&D
3.2.3 Scope of Major Pharma’s Partnering Activities in Targeted Protein Degradation (TPD)
4 Analysis of TPD Technologies
4.1 Analysis of Molecular Glue & Monovalent Proteasomal TPD Technologies
4.2 Analysis of Heterobifunctional Proteasomal TPD Technologies
4.3 Analysis of Lysosomal & Autophagy Pathway TPD Technologies
4.4 Remainder of TPD Technologies
5 Analysis of TPD Pipeline, Targets and Product Candidates
5.1 Molecular Glue & Monovalent Proteasomal Targeted Protein Degraders
5.1.1 Clinical & Non-Clinical Development Pipeline of Molecular Glue Degraders: Targets and Experience
5.1.2 Preclinical R&D Pipeline & Targets of Molecular Glue & Monovalent Protein Degraders
5.2 Heterobifunctional Proteasomal Targeted Protein Degraders
5.2.1 Clinical & Non-Clinical Development Pipeline of Heterobifunctional Degraders
5.2.2 Preclinical R&D Pipeline of Heterobifunctional Degraders
5.2.3 Protein-of-Interest Targets and E3 Ligases Addressed by Heterobifunctional Proteasomal Degraders
5.2.4 E3 Ligases and Binders
5.3 Lysosomal & Autophagy Pathway Protein Degraders
5.4 Remainder of Targeted Protein Degraders
6 Business, Financing & Partnering
7 Profiles of Stakeholders in Targeted Protein Degradation (TPD)
7.1 Pure-Play TPD Companies Focused on Molecular Glue & Monovalent Proteasomal Degraders
7.2 Pure-Play TPD Companies Focused on Heterobifunctional Proteasomal Degraders
7.3 Pure-Play TPD Companies Focused on Molecular Glue & Heterobifunctional Proteasomal Degraders
7.4 Pure-Play TPD Companies Focused on Lysosomal & Autophagic (Non-Proteasomal) Degraders
7.5 Diversified Technology Companies with One Focus on Heterobifunctional Proteasomal Degraders
7.6 Diversified Technology Companies with Various TPD Technology Profiles
7.7 Remainder of Technology Companies with Various TPD Technology Profiles
7.8 Pharmaceutical Companies with Stakes in Targeted Protein Degradation
7.9 Academia with TPD Industry Partnerships
8 Profiles of Targeted Protein Degradation (TPD) Technologies
8.1 Profiles of Molecular Glue & Monovalent TPD Technologies
8.2 Profiles of Heterobifunctional Proteasomal TPD Technologies
8.3 Profiles of Lysosomal & Autophagy Pathway TPD Technologies
8.4 Other TPD-Related Technologies
9 Profiles of TPD Product Candidates
9.1 Molecular Glue & Monovalent Protein Degraders
9.2 Heterobifunctional Proteasomal Targeted Protein Degraders
9.3 Lysosomal & Autophagy Pathway Protein Degraders
9.4 Remainder of Targeted Protein Degraders – Not Defined
10 References
ADDENDUM: Competitor Analysis
Add 1 Molecular Glue & Monovalent Small Molecule Proteasomal Targeted Protein Degradation
Add 2 Heterobifunctional Proteasomal Targeted Protein Degradation
Add 3 Lysosomal & Autophagy Pathway Targeted Protein Degradation
Add 4 Remainder of Targeted Protein Degradation
Companies Mentioned
AbbVie
Accelero Biostructures
Amgen
Amphista Therapeutics
AnHorn Medicines
Arvinas
Ascentage Pharma
Aurigene Discovery
AUTOTAC Bio
Bayer
BeiGene
Biogen
Biohaven Pharmaceutical Holding Company
BioTheryX
Blueprint Medicines
Boehringer Ingelheim
Bristol Myers Squibb
C4 Therapeutics
Calico
Calporta Therapeutics
Captor Therapeutics
Caraway Therapeutics
Casma Therapeutics
Celeris Therapeutics
Centessa Pharmaceuticals
Coho Therapeutics
ComInnex
Cullgen
Cullinan Oncology
Dalriada
Deargen
Debiopharm
Degron Therapeutics
Dialectic Therapeutics
Dunad Therapeutics
Eli Lilly
f5 Therapeutics
FIMECS
Frontier Medicines
Gilead Sciences
GlaxoSmithKline
Haisco Pharmaceutical Group
Hinova Pharmaceuticals
HitGen
Hoth Therapeutics
Insilico Medicines
Isoprene Pharmaceuticals
Janpix / Centessa Pharmaceuticals
Janssen Pharmaceutical Group of Companies
JW Pharmaceutical
Kangpu Biopharmaceuticals
Kymera Therapeutics
Lycia Therapeutics
Macroceutics (Hotspot Therapeutics)
Merck & Co
Merck KGaA
Monte Rosa Therapeutics
NeoImmuneTech
Novartis
Nurix Therapeutics
Origami Therapeutics
Orionis Biosciences
Orum Therapeutics
Pfizer
Pin Therapeutics
Plexion
Polymed Biopharmaceuticals
PolyProx Therapeutics
Prazer Therapeutics
Progenra
Proteovant Therapeutics
Proxygen
Ranok Therapeutics
Ribon Therapeutics
Roche
Ryvu Therapeutics
Sanofi
Seed Therapeutics
SK Holdings
Sosei Heptares
Trilo Therapeutics
Ubix Therapeutics
University of Dundee (Centre for Targeted Protein Degradation)
Uppthera
VectorY Therapeutics
Venquis Therapeutics
Vertex Pharmaceuticals
Vipergen
Vividion Therapeutics
Voronoi
XPose Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/2pz2id
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900